Roche\u2019s development engine is currently running at full speed. Within just a few days, the Basel-based pharmaceutical group was able to report several successes. First, the US Food and Drug Administration (FDA) granted the nerve drug «Enspryng» an accelerated review for the treatment of a rare autoimmune disease. Second, the pharmaceutical company secured worldwide rights from Chinese drugmaker Simcere to a promising drug candidate targeting B-cell diseases, including blood cancers. At the same time, another piece of good news emerged from China over the weekend: Roche partner MediLink reported strong Phase III data for the cancer drug «Tam-Peli». These developments are important for Roche participation certificates, as the shares need new fundamental arguments for a sustained attempt to break through their previous record level following their strong start to the year.<\/p>\n\n
Enspryng is particularly advanced, already approved in around 90 countries for another rare disease of the nervous system. The FDA has now accepted the supplemental application for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, for «Priority Review». MOGAD is a rare autoimmune disease of the central nervous system that can affect the optic nerves, brain and spinal cord, among other areas. There is currently no approved treatment for the disease. In a Phase III study, Enspryng reduced the risk of a relapse by 68% compared with placebo. After 48 weeks, 87% of treated patients remained relapse-free, compared with just over two-thirds in the control group. A decision by the FDA is expected by January 10, 2027. If successful, Enspryng would become the first approved disease-modifying therapy for MOGAD.<\/p>\n\n